Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been ...

The therapy demonstrated improvements in multiple cardiac measures ... leverage Evox’s DeliverEX platform to develop and ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

In addition, Imugene has made strides in expanding its trial. The Cohort Review Committee has cleared the first cohort of ...

DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and ...

AiCuris Anti-infective Cures has launched a first-in-human Phase I trial of AIC468, an antisense oligonucleotide designed to ...

Gene therapy involves the introduction of new genes into cells, to restore or add gene expression, for the purpose of treating disease. Most commonly a mutated gene is replaced with DNA encoding a ...

Humanistic therapy grew from humanistic psychology, a perspective of psychology that focuses on the individual and their inherent capacity to actualize themselves in their own unique ways. Humanistic ...

In a phase 3 trial, the biotech linked the antisense molecule to an 81% drop in the monthly rate of swelling attacks. Intellia is betting there is a market for a therapy with a similar level of ...